HAEMATEX
As your anticoagulant specialist, we work with you to provide innovative solutions for your laboratory. Helping you monitor patients to maintain their haemostatic balance.
Product Contact
We’d love to hear from you. Get in touch with us just below to request an offer!
DOAC-Stop™
DOAC-Stop™은 다비가트란, 에독사반, 베릭사반, 리바록사반, 아픽사반 및 아르가트로반을 포함한 모든 유형의 새로운 직접 경구용 항응고제(DOAC)를 혈액 응고 메커니즘에 관여하는 혈장 단백질에 미치는 영향을 최소화하면서 테스트 혈장에서 추출하는 최초의 제품입니다.
DOAC-Stop™은 10분 이내에 최대 2,000ng/ml의 모든 DOAC를 흡수합니다. 비타민 K 길항제나 헤파리노이드 항응고제와의 간섭은 미미합니다. DOAC-Stop™으로 처리된 혈장은 유효한 응고인자 분석과 혈전 위험 검사에 사용할 수 있습니다.
특히 루푸스 항응고제 검사에서 DOAC 또는 다른 약제로 인한 거짓 LA 양성 결과를 방지할 수 있습니다.
DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulants (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. There is negligible interference with vitamin K antagonists or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LA positive results due to DOACs or other agents in testing for lupus anticoagulants.
DOAC-Stop™ IS
DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulants (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. There is negligible interference with vitamin K antagonists or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LA positive results due to DOACs or other agents in testing for lupus anticoagulants.
해당 DOAC-Stop™은 RUO 제품입니다.
1. Exner T, et al. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. International Journal Laboratory Hematology 2020;00:1–8.
2. Favaloro E, et al. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research 180 (2019) 10–19
3. Slavic L, et al. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. Clinical and Applied Thrombosis/Hemostasis. 2019; Volume 25: 1-6
4. Zabczyk M, et al. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. De Gruyter Clin Chem Lab Med 2019;
5. Exner T, et al. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging agents. Clin Chem Lab Med. 2019; 57: 690-696.
6. Exner T, et al. Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent. Thromb Res 2019; 179: 69-72
7. Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban". Int J Lab Haematol. 2018; 1-7.
8. Exner T, et al. Simple method for removing DOACs from plasma samples Thromb. Res. 2018; 163: 117-122
CONTACT NOW
Are you interested in the product?
We’d love to hear from you. Get in touch with us just below to request an offer!